Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist
Francis S. Willard, Jonathan D. Douros, M Gabe, et al.
JCI Insight (2020) Vol. 5, Iss. 17
Open Access | Times Cited: 301

Showing 26-50 of 301 citing articles:

Targeting the incretin system in obesity and type 2 diabetes mellitus
Saleem Ansari, Bernard Khoo, Tricia Tan
Nature Reviews Endocrinology (2024) Vol. 20, Iss. 8, pp. 447-459
Closed Access | Times Cited: 30
Transforming obesity: The advancement of multi-receptor drugs
Christine M. Kusminski, Diego Pérez–Tilve, Timo D. Müller, et al.
Cell (2024) Vol. 187, Iss. 15, pp. 3829-3853
Closed Access | Times Cited: 24
GLP-1 physiology in obesity and development of incretin-based drugs for chronic weight management
Jens J. Holst
Nature Metabolism (2024) Vol. 6, Iss. 10, pp. 1866-1885
Open Access | Times Cited: 19
Tirzepatide prevents neurodegeneration through multiple molecular pathways
Rosaria Anna Fontanella, Puja Ghosh, Ada Pesapane, et al.
Journal of Translational Medicine (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 17
Mechanisms of action and therapeutic applications of GLP-1 and dual GIP/GLP-1 receptor agonists
Qiyuan Keith Liu
Frontiers in Endocrinology (2024) Vol. 15
Open Access | Times Cited: 16
Type 2 Diabetes Mellitus: New Pathogenetic Mechanisms, Treatment and the Most Important Complications
Ewelina Młynarska, Witold Czarnik, Natasza Dzieża, et al.
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 3, pp. 1094-1094
Open Access | Times Cited: 4
Are synthetic incretins associated with ischaemic optic neuropathy?
Victoria Gregory, Susan P. Mollan
Eye (2025)
Closed Access | Times Cited: 2
Glucose-dependent insulinotropic polypeptide (GIP)
Timo D. Müller, Alice E. Adriaenssens, Bo Ahrén, et al.
Molecular Metabolism (2025) Vol. 95, pp. 102118-102118
Open Access | Times Cited: 2
The promise of glucagon-like peptide 1 receptor agonists (GLP-1RA) for the treatment of obesity: a look at phase 2 and 3 pipelines
Sten Madsbad, Jens J. Holst
Expert Opinion on Investigational Drugs (2025), pp. 1-19
Open Access | Times Cited: 2
Targeting the GIPR for obesity: To agonize or antagonize? Potential mechanisms
Jonathan E. Campbell
Molecular Metabolism (2020) Vol. 46, pp. 101139-101139
Open Access | Times Cited: 86
Effects of Tirzepatide, a Dual GIP and GLP-1 RA, on Lipid and Metabolite Profiles in Subjects With Type 2 Diabetes
Valentina Pirro, Kenneth D. Roth, Yanzhu Lin, et al.
The Journal of Clinical Endocrinology & Metabolism (2021) Vol. 107, Iss. 2, pp. 363-378
Open Access | Times Cited: 83
The Role of Incretins on Insulin Function and Glucose Homeostasis
Jens J. Holst, Lærke S. Gasbjerg, Mette M. Rosenkilde
Endocrinology (2021) Vol. 162, Iss. 7
Open Access | Times Cited: 81
The Interplay of Glucagon-Like Peptide-1 Receptor Trafficking and Signalling in Pancreatic Beta Cells
Amaara Marzook, Alejandra Tomás, Ben Jones
Frontiers in Endocrinology (2021) Vol. 12
Open Access | Times Cited: 70
Emerging glucagon-like peptide 1 receptor agonists for the treatment of obesity
Mathies M. Jepsen, Mikkel Christensen
Expert Opinion on Emerging Drugs (2021) Vol. 26, Iss. 3, pp. 231-243
Closed Access | Times Cited: 70
Structural determinants of dual incretin receptor agonism by tirzepatide
Bingfa Sun, Francis S. Willard, Dan Feng, et al.
Proceedings of the National Academy of Sciences (2022) Vol. 119, Iss. 13
Open Access | Times Cited: 68
The Human Islet: Mini-Organ With Mega-Impact
John T. Walker, Diane C. Saunders, Marcela Briššová, et al.
Endocrine Reviews (2021) Vol. 42, Iss. 5, pp. 605-657
Open Access | Times Cited: 66
The dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide: a novel cardiometabolic therapeutic prospect
Enrique Z. Fisman, Alexander Tenenbaum
Cardiovascular Diabetology (2021) Vol. 20, Iss. 1
Open Access | Times Cited: 66
A survey of the mouse hindbrain in the fed and fasted states using single-nucleus RNA sequencing
Georgina K.C. Dowsett, Brian Lam, John A. Tadross, et al.
Molecular Metabolism (2021) Vol. 53, pp. 101240-101240
Open Access | Times Cited: 65
Spatiotemporal GLP-1 and GIP receptor signaling and trafficking/recycling dynamics induced by selected receptor mono- and dual-agonists
Aaron Novikoff, Shannon O’Brien, Miriam Bernecker, et al.
Molecular Metabolism (2021) Vol. 49, pp. 101181-101181
Open Access | Times Cited: 61
Pharmacogenomics of GLP-1 receptor agonists: a genome-wide analysis of observational data and large randomised controlled trials
Adem Y. Dawed, Andrea Mari, Andrew Brown, et al.
The Lancet Diabetes & Endocrinology (2022) Vol. 11, Iss. 1, pp. 33-41
Open Access | Times Cited: 55
Tirzepatide induces a thermogenic-like amino acid signature in brown adipose tissue
Ricardo J. Samms, Guo‐Fang Zhang, Wentao He, et al.
Molecular Metabolism (2022) Vol. 64, pp. 101550-101550
Open Access | Times Cited: 48
Tirzepatide: A Systematic Update
Imma Forzano, Fahimeh Varzideh, Roberta Avvisato, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 23, pp. 14631-14631
Open Access | Times Cited: 48
Clinical perspectives on the use of the GIP/GLP-1 receptor agonist tirzepatide for the treatment of type-2 diabetes and obesity
Baptist Gallwitz
Frontiers in Endocrinology (2022) Vol. 13
Open Access | Times Cited: 44
New therapies for obesity
Dimitris Papamargaritis, Carel W. le Roux, Jens J. Holst, et al.
Cardiovascular Research (2022) Vol. 119, Iss. 18, pp. 2825-2842
Open Access | Times Cited: 42
The postprandial actions of GLP-1 receptor agonists: The missing link for cardiovascular and kidney protection in type 2 diabetes
Merlin C. Thomas, Melinda T. Coughlan, Mark E. Cooper
Cell Metabolism (2023) Vol. 35, Iss. 2, pp. 253-273
Open Access | Times Cited: 33

Scroll to top